Uber's anti-epileptic innovative drug Vipit® (Lacacaamine tablets) has been approved by the State Drug Administration

today, Yousby announced that its anti-epilepticnew drug(http://Vipert ® (Lacacachamine tablets) has been approved by the NationalDrug(http://Supervision Authority for adults and adolescents (16-18 years old) epilepsy patients with or withor secondary full-blown seizures of partial combination of treatmentas the first third-generation anti-epilepticdrug(http://approved in the Chinese market in 11 years, Vepette ® with its new and unique focus to introduce new treatment options for some patients with epilepsya multicenter, randomized, placebo-controlled clinical
in chinese and Japanese adults with partial seizures
(http://confirmed that for patients who had been treated with 1 to 3 other anti-epileptic drugs at least 4 seizures per month, the proportion of patients who had a 50% decrease in seizures after combination with lacasamine was 49.2% (400mg/day) and 38.5% (200mg/day)unlike other anti-epileptic drug mechanisms on the market at present, Vepetti ® selective action on slow inactivated sodium channels, prolonging the sodium channel inactivation state time, can more effectively reduce the sodium ion internal current, reduce the excitability of neuronsIn addition to the Vepit ®, Uber®, the innovative drug used by Uber to treat Parkinson's disease, was launched in China in early November, and will be a boon to Chinese patients as the world's only transdermal patch for Parkinson's diseasein the coming years, Uber will also introduce more innovative drugs and solutions for the nervous system and immune system for the Chinese market for the benefit of more patients